Edgewise Therapeutics Future Growth
Future criteria checks 0/6
Edgewise Therapeutics is forecast to grow earnings and revenue by 0.06% and 84% per annum respectively. EPS is expected to grow by 4.4% per annum. Return on equity is forecast to be -34.2% in 3 years.
Key information
0.06%
Earnings growth rate
4.4%
EPS growth rate
Pharmaceuticals earnings growth | 24.0% |
Revenue growth rate | 84.0% |
Future return on equity | -34.2% |
Analyst coverage | Good |
Last updated | 19 Dec 2024 |
Recent future growth updates
Recent updates
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation
Nov 26Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)
Sep 19We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Aug 12Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal
Aug 05Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run
May 10We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate
May 10Edgewise Therapeutics: Behind The Massive Rally
Feb 18Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Dec 07Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
Aug 16Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Apr 28We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Jan 13Edgewise Therapeutics proposes $100M stock offering plan
Sep 13Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02
Aug 04Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Aug 02We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Mar 24We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Nov 23Edgewise Therapeutics names new chief medical officer
Apr 27Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 10 | -205 | N/A | -236 | 6 |
12/31/2025 | N/A | -175 | -121 | -139 | 7 |
12/31/2024 | N/A | -131 | -94 | -105 | 7 |
9/30/2024 | N/A | -124 | -110 | -109 | N/A |
6/30/2024 | N/A | -116 | -105 | -104 | N/A |
3/31/2024 | N/A | -106 | -99 | -98 | N/A |
12/31/2023 | N/A | -100 | -98 | -92 | N/A |
9/30/2023 | N/A | -89 | -86 | -77 | N/A |
6/30/2023 | N/A | -81 | -77 | -67 | N/A |
3/31/2023 | N/A | -76 | -72 | -63 | N/A |
12/31/2022 | N/A | -68 | -58 | -53 | N/A |
9/30/2022 | N/A | -61 | -53 | -50 | N/A |
6/30/2022 | N/A | -56 | -48 | -46 | N/A |
3/31/2022 | N/A | -51 | -41 | -40 | N/A |
12/31/2021 | N/A | -43 | -34 | -34 | N/A |
9/30/2021 | N/A | -36 | -29 | -29 | N/A |
6/30/2021 | N/A | -27 | -24 | -24 | N/A |
3/31/2021 | N/A | -21 | -18 | -18 | N/A |
12/31/2020 | N/A | -17 | -15 | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EWTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EWTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EWTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EWTX is forecast to have no revenue next year.
High Growth Revenue: EWTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EWTX is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/27 07:44 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Edgewise Therapeutics, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Cory Kasimov | Evercore ISI |
Madhu Kumar | Goldman Sachs |
Paul Choi | Goldman Sachs |